https://www.mynewsdesk.com/se/amgen Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/amgen https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Thu, 29 Jan 2026 07:00:00 +0100 https://www.mynewsdesk.com/se/amgen/pressreleases/ny-rapport-och-modell-vaegen-till-ett-mer-jaemlikt-och-strukturerat-omhaendertagande-av-hjaert-kaerlpatienter-3428974?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/ny-rapport-och-modell-vaegen-till-ett-mer-jaemlikt-och-strukturerat-omhaendertagande-av-hjaert-kaerlpatienter-3428974?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 19 Jun 2024 08:36:00 +0200 Behandling med Otezla leder till signifikant minskad axial inflammation hos patienter med tidig psoriasisartrit, PsA. Det visar nya resultat från MOSAIC, den första kliniska prövningen där inflammation bedöms med magnetkamera. Det är ett av flera exempel på nyheter om Otezla vid PsA som presenterats på Europas viktigaste kongress inom reumatologi, EULAR 2024. https://www.mynewsdesk.com/se/amgen/pressreleases/eular-2024-otezla-reducerar-axial-inflammation-hos-patienter-med-psoriasisartrit-3330743?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/eular-2024-otezla-reducerar-axial-inflammation-hos-patienter-med-psoriasisartrit-3330743?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Mon, 13 Nov 2023 09:44:24 +0100 https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-cardiovascular-research-at-aha-2023-3285766?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-cardiovascular-research-at-aha-2023-3285766?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Mon, 13 Nov 2023 09:23:00 +0100 https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023-3285757?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023-3285757?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Thu, 26 Oct 2023 08:27:00 +0200 En förstärkt trend till förbättrad återfallsfri överlevnad i och med signifikant förbättrad sjukdomsfri överlevnad och lägre risk för cancerspecifik död. Det är resultatet av tillägg av Vectibix till neoadjuvant kemoterapi för patienter med operabel tjocktarmscancer av RAS/BRAF-vildtyp. Den nya analysen från FOxTROT-studien presenterades på ESMO-kongressen i Madrid. https://www.mynewsdesk.com/se/amgen/pressreleases/lovande-resultat-med-panitumumab-i-tillaegg-till-neoadjuvant-kemoterapi-vid-kolorektalcancer-3281829?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/lovande-resultat-med-panitumumab-i-tillaegg-till-neoadjuvant-kemoterapi-vid-kolorektalcancer-3281829?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 25 Oct 2023 08:38:00 +0200 Nya data för xaluritamig (AMG509), en målriktad immunterapi mot STEAP1, visar lovande effekt mot metastaserande kastrationsresistent prostatacancer. Det visar data som presenterats på ESMO-kongressen i Madrid. – Det faktum att tungt förbehandlade patienter svarar så pass bra väcker onekligen hopp, säger Ingrida Verbiené, onkolog och överläkare vid Akademiska sjukhuset i Uppsala. https://www.mynewsdesk.com/se/amgen/pressreleases/esmo-2023-riktad-immunterapi-lovande-mot-spridd-prostatacancer-3281745?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/esmo-2023-riktad-immunterapi-lovande-mot-spridd-prostatacancer-3281745?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Tue, 24 Oct 2023 08:22:00 +0200 En kombination av Lumykras och Vectibix gav signifikant förbättrad progressionsfri överlevnad hos patienter med metastaserande KRAS G12C-muterad kolorektalcancer jämfört med standardbehandling. Det visar nya data från fas III-studien CodeBreaK 300 som presenteras på ESMO-kongressen i Madrid. https://www.mynewsdesk.com/se/amgen/pressreleases/esmo-2023-signifikant-baettre-resultat-med-sotorasib-kombination-vid-spridd-tjock-och-aendtarmscancer-3281423?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/esmo-2023-signifikant-baettre-resultat-med-sotorasib-kombination-vid-spridd-tjock-och-aendtarmscancer-3281423?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Fri, 22 Sep 2023 10:43:43 +0200 AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients. Inaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-launches-partners-of-choice-network-of-eight-leading-oncology-academic-centers-3274936?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-launches-partners-of-choice-network-of-eight-leading-oncology-academic-centers-3274936?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Mon, 11 Sep 2023 14:52:15 +0200 AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-lumakras-r-slash-lumykras-r-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-at-wclc-3272227?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-presents-new-lumakras-r-slash-lumykras-r-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-at-wclc-3272227?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Thu, 15 Jun 2023 08:33:00 +0200 Data från fas IV-studien MOSAIC som presenterats på den stora kongressen EULAR visar, med hjälp av magnetkamera, att behandling med Otezla har god effekt för att dämpa inflammation i perifera leder och muskelfästen hos patienter med psoriasisartrit. https://www.mynewsdesk.com/se/amgen/pressreleases/positiva-data-foer-otezla-vid-psoriasisartrit-paa-eular-3259529?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/positiva-data-foer-otezla-vid-psoriasisartrit-paa-eular-3259529?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Thu, 08 Jun 2023 08:37:00 +0200 https://www.mynewsdesk.com/se/amgen/pressreleases/positiva-resultat-foer-kombinationsbehandling-med-kras-g12c-haemmare-vid-kolorektalcancer-paa-asco-3257516?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/positiva-resultat-foer-kombinationsbehandling-med-kras-g12c-haemmare-vid-kolorektalcancer-paa-asco-3257516?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 07 Jun 2023 08:33:00 +0200 Lumykras i kombination med kemoterapi gav en objektiv tumörrespons på 88,9 procent och var tolerabelt vid behandling i första linjen av patienter med icke-småcellig KRAS G12C-muterad lungcancer. Det visar data från en studie som presenterades på ASCO nu i helgen. – Det är onekligen hoppingivande data, säger docent Jan Nyman, överläkare vid Sahlgrenska Universitetssjukhuset. https://www.mynewsdesk.com/se/amgen/pressreleases/asco-2023-lovande-resultat-med-lumykras-i-kombination-med-kemoterapi-i-foersta-linjen-mot-lungcancer-3257478?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/asco-2023-lovande-resultat-med-lumykras-i-kombination-med-kemoterapi-i-foersta-linjen-mot-lungcancer-3257478?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Thu, 08 Dec 2022 08:32:00 +0100 På lördag den 10 december inleds ASH, världens största blodcancerkongress, i New Orleans. Ett så kallat Late Breaking Abstract visar på överlevnadsfördelar hos vuxna patienter i första linjens behandling då Blincyto ges som tillägg till kemoterapi vid Philadelphia-negativ akut lymfatisk B-cellsleukemi (B-ALL). https://www.mynewsdesk.com/se/amgen/pressreleases/konsolidering-med-blincyto-foerlaenger-oeverlevnad-vid-akut-lymfatisk-leukemi-3222427?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/konsolidering-med-blincyto-foerlaenger-oeverlevnad-vid-akut-lymfatisk-leukemi-3222427?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 16 Nov 2022 11:28:49 +0100 New Real-World Evidence Highlights AMGEVITA® Utilization, Treatment Satisfaction and Persistence in European Patients New Data From First-in-Class Treatment TAVNEOS®, Evaluating Renal Function Among Adults Living With Severe Active ANCA-Associated Vasculitis https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-to-present-new-research-across-serious-inflammatory-and-bone-diseases-at-acr-2022-3217893?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-to-present-new-research-across-serious-inflammatory-and-bone-diseases-at-acr-2022-3217893?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 14 Sep 2022 23:56:08 +0200 LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate https://www.mynewsdesk.com/se/amgen/pressreleases/lumakras-r-slash-lumykras-r-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-3204316?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/lumakras-r-slash-lumykras-r-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-3204316?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Tue, 13 Sep 2022 10:33:26 +0200 Barn med psoriasis blir signifikant bättre av behandling med Otezla. Det visar data som presenterats vid EADV-kongressen i Milano. – Det här är hoppingivande då det finns begränsat med perorala systemiska behandlingsalternativ för barn med psoriasis, säger dermatolog Enikö Sonkoly. På kongressen presenterades också positiva data på Otezla vid behandling av genital psoriasis. https://www.mynewsdesk.com/se/amgen/pressreleases/eadv-2022-otezla-ger-signifikant-foerbaettring-av-psoriasis-hos-barn-3203471?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/eadv-2022-otezla-ger-signifikant-foerbaettring-av-psoriasis-hos-barn-3203471?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Wed, 31 Aug 2022 23:27:14 +0200 AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an Upcoming Medical Congress https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-announces-topline-data-from-lumakras-r-sotorasib-phase-3-trial-in-non-small-cell-lung-cancer-3200989?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-announces-topline-data-from-lumakras-r-sotorasib-phase-3-trial-in-non-small-cell-lung-cancer-3200989?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Mon, 29 Aug 2022 15:19:02 +0200 Finala data från långtidsuppföljningen av fas III-studien FOURIER visar att Repatha, ger ihållande kolesterolsänkning som är långsiktigt säker och tolereras väl. ”Här ser vi att tidigt insatt och långvarig behandling med Repatha inte bara är säkert, utan också ger ett signifikant förbättrat skydd mot allvarliga kardiovaskulära händelser inklusive dödsfall”, säger professor Mats Eriksson. https://www.mynewsdesk.com/se/amgen/pressreleases/laangtidsdata-paa-esc-2022-repatha-raeddar-liv-och-tolereras-vael-efter-mer-aen-aatta-aar-3200257?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/laangtidsdata-paa-esc-2022-repatha-raeddar-liv-och-tolereras-vael-efter-mer-aen-aatta-aar-3200257?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Tue, 23 Aug 2022 00:03:36 +0200 Late-breaking Hot Line Oral Presentation on FOURIER-OLE Data Represents Longest Trials of a PCSK9i to Date New HEYMANS, HAUSER Data to be Presented https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-to-present-new-data-at-esc-congress-2022-highlighting-up-to-8-punkt-5-years-of-repatha-r-evolocumab-safety-and-tolerability-data-in-high-risk-ascvd-patient-populations-3198991?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/amgen-to-present-new-data-at-esc-congress-2022-highlighting-up-to-8-punkt-5-years-of-repatha-r-evolocumab-safety-and-tolerability-data-in-high-risk-ascvd-patient-populations-3198991?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB Mon, 15 Aug 2022 08:34:00 +0200 På just avslutade världskongressen för lungcancer, WCLC 2022, presenterades nya data på KRASG12C-hämmaren Lumykras i lovande kombinationsbehandlingar med såväl signaltransduktionshämmare mot SHP2 som immuncheckpointhämmare. https://www.mynewsdesk.com/se/amgen/pressreleases/wclc-2022-lovande-data-foer-lumykras-som-del-i-kombinationsbehandling-mot-kras-g12c-muterad-lungcancer-3197608?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/amgen/pressreleases/wclc-2022-lovande-data-foer-lumykras-som-del-i-kombinationsbehandling-mot-kras-g12c-muterad-lungcancer-3197608?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Amgen AB